Skip to content

Study on the safety and efficacy of soothing and repairing products containing astragalus extract combined with yellow light irradiation for the treatment of sensitive skin

Study on the safety and efficacy of soothing and repairing products containing astragalus extract combined with yellow light irradiation for the treatment of sensitive skin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109298
Enrollment
Unknown
Registered
2025-09-16
Start date
2025-09-20
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitive skin

Interventions

Trial Group:Subjects must visit the clinic twice weekly for yellow light therapy (590 nm +/- 10 nm, 10 minutes per session), and after treatment, apply Yuyanqi Soothing Repair Moisturizing Astragalus

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 45 years, Chinese males and females; 2. Good general health; 3. Meet the diagnostic criteria for sensitive skin; 4. Diagnosed with sensitive skin for more than one year; 5. Willing to comply with trial requirements, complete the full 2-month study, and adhere to follow-up procedures.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Individuals with known hypersensitivity to cosmetics, soaps, rubber, alcohol, fragrance ingredients, or other topical agents or medications; 3. Presence of skin diseases (e.g., psoriasis, eczema, cutaneous malignancy) or significant skin abnormalities (e.g., open wounds, tattoos, scars) in or near the test area that may interfere with evaluation; 4. Use of topical retinoids, corticosteroids, tacrolimus, or other agents affecting skin barrier function or immune status within 2 weeks prior to enrollment, or use of any other topical drugs or medical skincare products within 1 week prior to enrollment; 5. Participation in another clinical trial within the past 6 months; 6. Abnormal liver or renal function, or presence of other systemic diseases; 7. Excessively high expectations regarding treatment efficacy; 8. Patients with sensitive skin who have demonstrated poor response to conventional first-line therapies.

Design outcomes

Primary

MeasureTime frame
West China Sensitive Skin Assessment;Physician's Global Assessment (PGA);Lactic acid stinging test score;Clinical Erythema Assessment;

Secondary

MeasureTime frame
Trans Epidermal Water Loss;Skin moisture content;Skin oil content;VISIA testing;Patient treatment satisfaction;Dermatology Quality of Life Scale;

Countries

China

Contacts

Public ContactJiang Xian

West China Hospital of Sichuan University

jiangxian@scu.edu.cn+86 189 8060 1693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026